Zhang Xiao-Bin, Yuan Ya-Ting, Du Yan-Ping, Jiang Xing-Tang, Zeng Hui-Qing
Department of Respiratory Medicine, Zhongshan Hospital, Xiamen University, No. 201, Hubin Nan Road, Siming District, Xiamen, 361004, Fujian, China,
Lung. 2015 Apr;193(2):255-60. doi: 10.1007/s00408-015-9684-z. Epub 2015 Jan 15.
Positive airway pressure (PAP) has been recognized as an effective therapeutic option for sleep-disordered breathing (SDB) in patients with heart failure (HF), and it can improve left ventricular function. Whether PAP can ameliorate serum brain natriuretic peptide (BNP) levels, a biomarker of HF, is controversial. The purpose of the present study was to quantitatively assess the efficacy of PAP on BNP in patients with HF and SDB.
A systematic search of PubMed, Embase, Web of Science and Cochrane library identified six randomized controlled trials (RCTs), in which PAP was compared with medical therapy, subtherapeutic PAP or different types of PAP. The data of BNP were extracted and pooled into meta-analysis using STATA 12.0.
Totally 6 RCT studies (7 cohorts) with 222 patients were enrolled into analysis. The quality of each study was high and the heterogeneity (I(2) = 58.1%) was noted between studies. A significant reduction of BNP was observed after PAP treatment in patients with HF and SDB (SMD -0.517, 95% CI -0.764 to -0.270, z = 4.11, p = 0.000).
Our meta-analysis of RCTs demonstrated that PAP elicits significant reduction of BNP in patients with HF and SDB.
气道正压通气(PAP)已被公认为是心力衰竭(HF)合并睡眠呼吸障碍(SDB)患者睡眠呼吸障碍的一种有效治疗选择,并且它可以改善左心室功能。PAP是否能改善血清脑钠肽(BNP)水平(一种HF的生物标志物)存在争议。本研究的目的是定量评估PAP对HF合并SDB患者BNP的疗效。
对PubMed、Embase、科学引文索引和考克兰图书馆进行系统检索,确定了6项随机对照试验(RCT),其中将PAP与药物治疗、亚治疗性PAP或不同类型的PAP进行了比较。提取BNP的数据,并使用STATA 12.0将其汇总进行荟萃分析。
共有6项RCT研究(7个队列)、222例患者纳入分析。每项研究的质量都很高,并且研究之间存在异质性(I² = 58.1%)。在HF合并SDB患者中,PAP治疗后观察到BNP显著降低(标准化均数差-0.517,95%可信区间-0.764至-0.270,z = 4.11,p = 0.000)。
我们对RCT的荟萃分析表明,PAP可使HF合并SDB患者的BNP显著降低。